Monte Rosa Therapeutics Announced Progress Updates For Its Two Lead Programs, MRT-2359, An MGD Being Developed For MYC-Driven Solid Tumors, And MRT-6160, A VAV1-directed MGD In Development For Systemic And Neurological Autoimmune Diseases
Monte Rosa Therapeutics Announced Progress Updates For Its Two Lead Programs, MRT-2359, An MGD Being Developed For MYC-Driven Solid Tumors, And MRT-6160, A VAV1-directed MGD In Development For Systemic And Neurological Autoimmune Diseases
蒙特罗萨治疗公司发布了两个主要计划的进展更新，即MRT-2359和MRT-6160。其中，MRT-2359是针对MYC驱动的实体肿瘤而开发的MDG，而MRT-6160则是针对系统性和神经免疫疾病而开发的VAV1定向MDG。
- Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level; final determination of recommended Phase 2 dose and updated clinical results anticipated in H2 2024.
- IND submission achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; initiation of Phase 1 SAD/MAD study expected this summer with Phase 1 clinical data anticipated in Q1 2025.
- MRT-2359用于MYC驱动的实体肿瘤的1/2期临床研究表现出良好的安全性和药效学特征，0.5毫克剂量采用21/7计划; 目前正在评估0.75毫克剂量水平; 推荐的2期剂量的最终确定以及更新的临床结果预计将于2024下半年出炉。
- MRT-6160是面向系统性和神经自身免疫疾病开发的以VAV1为靶向的多肽药物，并已完成IND提交; SAD/MAD 1期临床研究预计于今年夏季启动，1期临床数据预计于2025 Q1公布。